Precision diagnosis and standardized treatment of mid-low rectal cancer
10.3760/cma.j.cn115610-20231211-00248
- VernacularTitle:中低位直肠癌的精准诊断与规范治疗
- Author:
Yun YANG
1
;
Chenglin XIN
;
Zhongtao ZHANG
Author Information
1. 首都医科大学附属北京友谊医院普通外科中心 国家消化系统疾病临床医学研究中心 消化健康全国重点实验室，北京 100050
- Keywords:
Rectal neoplasms;
Chinese colorectal cancer surgery database;
Chinese trans-anal total mesorectal excision registry collaborative;
Immunotherapy;
Neo-adju
- From:
Chinese Journal of Digestive Surgery
2024;23(1):85-90
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer is a major digestive disease in China, with mid-low rectal cancer as the predominant cause. Over the years, Chinese colorectal surgery has made considerable strides, attaining certain successes in clinical diagnosis and treatment, scientific research, and data platform construction. Nevertheless, there is still room for improvement in terms of the accuracy of diagnosis and standardization of treatment. Furthermore, immune checkpoint therapy represented by programmed death-1 have demonstrated initial efficacy in the treatment of mid-low rectal cancer. Further research is required to better understand the relationship and role between immune checkpoint inhibitors and traditional radiotherapy and chemotherapy, and to apply them to precise clinical practice. The authors elaborate on current status of diagnosis and treatment for mid-low rectal cancer in China, in order to provide references for its precission diagnosis and standardized treatment.
